Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Niagen Bioscience (NAGE) Shares Outstanding (Diluted Average) (2016 - 2025)

Niagen Bioscience (NAGE) has disclosed Shares Outstanding (Diluted Average) for 13 consecutive years, with $85.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Shares Outstanding (Diluted Average) rose 9.36% to $85.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $85.4 million, a 9.36% increase, with the full-year FY2025 number at $85.4 million, up 9.36% from a year prior.
  • Shares Outstanding (Diluted Average) was $85.4 million for Q4 2025 at Niagen Bioscience, down from $86.6 million in the prior quarter.
  • In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $86.6 million in Q3 2025 to a low of $64.2 million in Q1 2021.
  • A 5-year average of $74.3 million and a median of $75.0 million in 2023 define the central range for Shares Outstanding (Diluted Average).
  • Peak YoY movement for Shares Outstanding (Diluted Average): grew 0.58% in 2024, then increased 14.14% in 2025.
  • Niagen Bioscience's Shares Outstanding (Diluted Average) stood at $67.2 million in 2021, then increased by 3.79% to $69.7 million in 2022, then rose by 7.54% to $75.0 million in 2023, then increased by 4.19% to $78.1 million in 2024, then increased by 9.36% to $85.4 million in 2025.
  • Per Business Quant, the three most recent readings for NAGE's Shares Outstanding (Diluted Average) are $85.4 million (Q4 2025), $86.6 million (Q3 2025), and $86.2 million (Q2 2025).